Maarssen, Netherlands, Netherlands · Est. 1911
Solvay Pharmaceuticals was a pharmaceutical company focused on neurology, psychiatry, and respiratory treatments that was acquired by Abbott Laboratories in 2010.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
Regulatory
Lithobid — ESKALITH CR
Application NDA018152 (NDA)
Lithobid — LITHIUM CARBONATE
Application NDA018558 (NDA)
Lithobid — LITHONATE
Application NDA017672 (NDA)
Lithobid — LITHONATE
Application NDA016782 (NDA)
Chronulac — CHRONULAC
Application NDA017884 (NDA)
Lithobid — LITHOBID
Application NDA018027 (NDA)
Lithobid — ESKALITH
Application NDA017971 (NDA)
Lithobid — LITHIUM CITRATE
Application NDA018421 (NDA)
Lithobid — LITHIUM CARBONATE
Application NDA016834 (NDA)
Lithobid — LITHOTABS
Application NDA016980 (NDA)
Gynorest — GYNOREST
Application NDA017388 (NDA)
Chronulac — LACTULOSE
Application NDA017906 (NDA)
Lithobid — ESKALITH
Application NDA016860 (NDA)
Chronulac — CEPHULAC
Application NDA017657 (NDA)
Lithobid — LITHANE
Application NDA018833 (NDA)
Lithobid — LITHIUM CARBONATE
Application NDA017812 (NDA)
Luvox — LUVOX
Application NDA020243 (NDA)
Luvox — LUVOX
Application NDA021519 (NDA)
Luvox — LUVOX CR
Application NDA022033 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)